C

Cellivery Therapeutics Inc
KOSDAQ:268600

Watchlist Manager
Cellivery Therapeutics Inc
KOSDAQ:268600
Watchlist
Price: 6 680 KRW -29.91% Market Closed
Market Cap: ₩594.9m

Net Margin

-25%
Current
Improving
by 339.1%
vs 3-y average of -364.1%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-25%
=
Net Income
₩-6.1B
/
Revenue
₩24.5B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-25%
=
Net Income
₩-6.1B
/
Revenue
₩24.5B

Peer Comparison

Country Company Market Cap Net
Margin
KR
Cellivery Therapeutics Inc
KOSDAQ:268600
594.9m KRW
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.3T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
236.2B USD
Loading...
US
Danaher Corp
NYSE:DHR
166.4B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
82.9T KRW
Loading...
CH
Lonza Group AG
SIX:LONN
38.3B CHF
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
41.4B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
272.7B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
38.7B USD
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
29.3B USD
Loading...
FR
Sartorius Stedim Biotech SA
PAR:DIM
19.9B EUR
Loading...

Market Distribution

Lower than 86% of companies in Korea
Percentile
14th
Based on 2 632 companies
14th percentile
-25%
Low
-168 471.3% — -2.9%
Typical Range
-2.9% — 5.8%
High
5.8% — 21 012.5%
Distribution Statistics
Korea
Min -168 471.3%
30th Percentile -2.9%
Median 1.9%
70th Percentile 5.8%
Max 21 012.5%

Cellivery Therapeutics Inc
Glance View

Cellivery Therapeutics, Inc. engages in the research and development of medicine and pharmacy. The company is headquartered in Seoul, Seoul. The company went IPO on 2018-11-09. The firm develops biotherapeutics capable of entering cells in vivo through proprietary therapeuticmolecule systemic delivery technology (TSDT). The firm research and develop therapeutic drug candidates such as Parkinson’s disease treatment, pancreatic cancer and solid cancer treatment, bone formation promoter, as well as advanced obesity & type II diabetes mellitus; new drugs for research including DNA recombinase and reprogramming factors (RFs).

Intrinsic Value
Not Available
C
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-25%
=
Net Income
₩-6.1B
/
Revenue
₩24.5B
What is Cellivery Therapeutics Inc's current Net Margin?

The current Net Margin for Cellivery Therapeutics Inc is -25%, which is above its 3-year median of -364.1%.

How has Net Margin changed over time?

Over the last 3 years, Cellivery Therapeutics Inc’s Net Margin has increased from -6 812.9% to -25%. During this period, it reached a low of -6 812.9% on Aug 30, 2021 and a high of -25% on Oct 30, 2024.

Back to Top